United States of America

Last Updated 2 December 2022.

6 Vaccines Approved for Use in United States of America

• Novavax
  Nuvaxovid

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 40 countries

  22 trials in 14 countries

  Approval Source: fda.gov

  Protein Subunit

• Moderna
  Spikevax

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 88 countries

  70 trials in 24 countries

  Approval Source: bbc.com

  RNA

• Moderna
  Spikevax Bivalent Original/Omicron BA.4/BA.5

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 33 countries

  2 trials in 1 country

  Approval Source: fda.gov

  RNA

• Pfizer/BioNTech
  Comirnaty

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 149 countries

  100 trials in 31 countries

  Approval Source: nytimes.com

  RNA

• Pfizer/BioNTech
  Comirnaty Bivalent Original/Omicron BA.4/BA.5

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 33 countries

  4 trials in 1 country

  Approval Source: fda.gov

  RNA

• Janssen (Johnson & Johnson)
  Jcovden

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 113 countries

  26 trials in 25 countries

  Approval Source: nytimes.com

  Non Replicating Viral Vector

52 Vaccines in Clinical Trials in United States of America

• Novavax
  Nuvaxovid

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 40 countries

  22 trials in 14 countries

  Protein Subunit

• COVAXX
  UB-612

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  7 trials in 2 countries

  Protein Subunit

• Sanofi/GSK
  VidPrevtyn Beta

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 30 countries

  3 trials in 2 countries

  Protein Subunit

• Sanofi/GSK
  Recombinant Protein

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  6 trials in 7 countries

  Protein Subunit

• Medicago
  Covifenz

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  6 trials in 6 countries

  VLP

• Radboud University
  ABNCoV2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 3 countries

  VLP

• Inovio
  INO-4800

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  10 trials in 9 countries

  DNA

• Arcturus Therapeutics Inc
  ARCT-154

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  6 trials in 3 countries

  RNA

• Pfizer/BioNTech
  Comirnaty Bivalent Original/Omicron BA.4/BA.5

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 33 countries

  4 trials in 1 country

  RNA

• Pfizer/BioNTech
  Comirnaty Bivalent Original/Omicron BA.1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 35 countries

  3 trials in 5 countries

  RNA

• Pfizer/BioNTech
  Comirnaty

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 149 countries

  100 trials in 31 countries

  RNA

• Pfizer/BioNTech
  BNT162b2s01

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 2 countries

  RNA

• Pfizer/BioNTech
  BNT162b1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 3 countries

  RNA

• Moderna
  Spikevax Bivalent Original/Omicron BA.4/BA.5

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 33 countries

  2 trials in 1 country

  RNA

• Moderna
  Spikevax Bivalent Original/Omicron BA.1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 38 countries

  5 trials in 4 countries

  RNA

• Moderna
  Spikevax

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 88 countries

  70 trials in 24 countries

  RNA

• Moderna
  mRNA-1273.617.2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  2 trials in 1 country

  RNA

• Moderna
  mRNA-1273.213

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  2 trials in 1 country

  RNA

• Moderna
  mRNA-1273.211

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 1 country

  RNA

• Oxford/AstraZeneca
  Vaxzevria

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 149 countries

  73 trials in 34 countries

  Non Replicating Viral Vector

• Mahidol University
  NDV-HXP-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  7 trials in 3 countries

  Non Replicating Viral Vector

• Janssen (Johnson & Johnson)
  Jcovden

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 113 countries

  26 trials in 25 countries

  Non Replicating Viral Vector

• Bharat Biotech
  Covaxin

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 14 countries

  16 trials in 2 countries

  Inactivated

• Sinopharm (Beijing)
  Covilo

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 93 countries

  39 trials in 18 countries

  Inactivated

• Kentucky Bioprocessing
  KBP-201

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Arcturus Therapeutics Inc
  ARCT-165

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 2 countries

  RNA

• Arcturus Therapeutics Inc
  LUNAR-COV19/ARCT-021

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  6 trials in 2 countries

  RNA

• Moderna
  mRNA-1073

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Moderna
  mRNA-1283

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Moderna
  mRNA-1283.211

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 1 country

  RNA

• Pfizer/BioNTech
  BNT162b2 (B.1.1.7 + B.1.617.2)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 4 countries

  RNA

• Pfizer/BioNTech
  BNT162b2 (B.1.1.7)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 4 countries

  RNA

• Pfizer/BioNTech
  BNT162b2 (B.1.617.2)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 4 countries

  RNA

• Pfizer/BioNTech
  BNT162b5 Bivalent (WT/OMI BA.2)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• ImmunityBio Inc
  hAd5-Covid-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  7 trials in 2 countries

  Non Replicating Viral Vector

• Vaxart
  VXA-CoV2-1.1-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Aivita Biomedical Inc
  AV-COVID-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  4 trials in 2 countries

  Replicating Viral Vector

• City of Hope Medical Center
  COH04S1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Replicating Viral Vector

• US Army Medical Research and Development Command
  SpFN COVID-19 Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• Speransa Therapeutics
  PRIME-2-CoV_Beta

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 2 countries

  Protein Subunit

• Providence Health & Services
  CORVax12

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  DNA

• GlaxoSmithKline
  CoV2 SAM (LNP)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• GlaxoSmithKline
  CV0501

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 3 countries

  RNA

• GlaxoSmithKline
  CV2CoV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• HDT Bio
  HDT-301

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• Moderna
  mRNA-1230

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 3 countries

  RNA

• Moderna
  mRNA-1273.351

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• CyanVac LLC
  CVXGA1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• NIAID
  ChAdV68-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• NIAID
  SAM-LNP-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Vaxart
  VXA-CoV2-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Meissa Vaccines Inc
  MV-014-212

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Replicating Viral Vector

4 Vaccines with Trials in United States of America are No Longer Progressing

• Sanofi Pasteur
  MRT5500

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  2 trials in 1 country

  RNA

• Altimmune Inc
  AdCOVID

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Merck Sharp & Dohme Corp
  V590

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Replicating Viral Vector

• Merck Sharp & Dohme Corp
  V591

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  2 trials in 3 countries

  Replicating Viral Vector